Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) CEO Charles Divita III sold 19,132 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Charles Divita III also recently made the following trade(s):
- On Wednesday, March 11th, Charles Divita III sold 27,731 shares of Teladoc Health stock. The shares were sold at an average price of $5.49, for a total value of $152,243.19.
Teladoc Health Stock Down 3.6%
Teladoc Health stock opened at $7.05 on Friday. The company has a market cap of $1.27 billion, a PE ratio of -7.26 and a beta of 2.14. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.77. The stock’s 50 day moving average price is $6.20 and its 200 day moving average price is $6.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72.
Analyst Ratings Changes
Several research firms have recently commented on TDOC. Piper Sandler reiterated an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Leerink Partners decreased their target price on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research report on Thursday, February 26th. Oppenheimer lowered their price target on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, March 3rd. Barclays cut their target price on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Finally, Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.43.
Check Out Our Latest Report on TDOC
Institutional Trading of Teladoc Health
Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its holdings in Teladoc Health by 694.5% in the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 4,945 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Teladoc Health by 412.1% in the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares in the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of Teladoc Health by 101.1% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock worth $37,000 after purchasing an additional 2,425 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of Teladoc Health during the fourth quarter worth about $45,000. Institutional investors and hedge funds own 76.82% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Featured Articles
- Five stocks we like better than Teladoc Health
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
